Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata

Authors

Cunshan Wang
Sergio Vañó‐Galván (ORCID: https://orcid.org/0000-0003-2773-7494)
Satrajit Roychoudhury (ORCID: https://orcid.org/0000-0003-4001-3036)
Dalia Wajsbrot
Amy J. McMichael (ORCID: https://orcid.org/0000-0002-5342-2181)
Rodney Sinclair (ORCID: https://orcid.org/0000-0001-6751-1428)
Ernest H. Law (ORCID: https://orcid.org/0000-0002-6111-8008)
Brett King (ORCID: https://orcid.org/0000-0002-4576-4616)
Alexandre Lejeune
Deborah Woodworth
Feriel Robbana
Robert A. Wolk (ORCID: https://orcid.org/0000-0001-8581-6647)
Lynne Napatalung
Koshika Soma

Institutions

Pfizer (United States) (US)
Instituto Cajal (ES)
Pfizer (France) (FR)
Sinclair Dermatology (AU)
Pfizer (Canada) (CA)
Wake Forest University (US)
Icahn School of Medicine at Mount Sinai (US)

Publication Details

Journal: Dermatology and Therapy
Published: 2025-10-14
DOI: https://doi.org/10.1007/s13555-025-01543-7
Citations: 1
Primary Topic: Hair Growth and Disorders
Type: article
Field-Weighted Citation Impact: 1.84

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata

Cunshan Wang, Sergio Vañó‐Galván, Satrajit Roychoudhury, Dalia Wajsbrot et al.

Oct 14, 2025

1 citations

Dermatology and Therapy

Hair Growth and Disorders

1.84

article

Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata

Cunshan Wang, Sergio Vañó‐Galván, Satrajit Roychoudhury, Dalia Wajsbrot, Amy J. McMichael, Rodney Sinclair, Ernest H. Law, Brett King, Alexandre Lejeune, Deborah Woodworth, Feriel Robbana, Robert A. Wolk, Lynne Napatalung, Koshika Soma

October 14, 2025article en

1 citations

Abstract

No abstract available for this paper.

Dermatology and TherapyVol. 15(12)

Pfizer (United States) (US), Instituto Cajal (ES), Pfizer (France) (FR), Sinclair Dermatology (AU), Pfizer (Canada) (CA), Wake Forest University (US), Icahn School of Medicine at Mount Sinai (US)

Openalex Percentile: Top 12%

Hair Growth and Disorders

1.84

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.